Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026
Read more
NEWS & MEDIA
Read our recent announcements
Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026
Press
October 26, 2026
Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers
Read more
All
Press
Publications
Presentations
Presentation
July 15, 2025
Presentation at the Gordon Research Conference: Computer Aided Drug Design
Read more
Press
July 9, 2025
Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates
Read more
Press
June 26, 2025
Iambic takes the lead for Next-Gen AI Drug Discovery with Lambda
Read more
Press
June 10, 2025
Iambic Named to CNBC’s 2025 Disruptor 50 List
Read more
Press
June 4, 2025
Iambic Completes Dose Escalation in Ongoing Phase 1/1B Study of Lead Program IAM1363, a Small Molecule Inhibitor of Wild-Type and Oncogenic HER2 Mutant Proteins
Read more
Press
May 28, 2025
Iambic to Participate in June Investor Conferences
Read more
Presentation
May 13, 2025
Panel presentation at the Bank of America Healthcare Conference
Read more
Press
May 5, 2025
Iambic Announces Enchant v2, its Next Generation AI Model for Predicting the Clinical Viability of Drug Discovery Programs
Read more
Publication
May 5, 2025
Enchant v2: Pushing the Boundaries of Predictive Drug Discovery
Read more
Press
Announcement
September 5, 2024
Iambic Therapeutics Announces the Addition of Dr. Mary Tagliaferri to its Board of Directors
Read more
Press
Announcement
June 18, 2024
How two academic chemists turned San Diego startup Iambic into an AI force
Read more
Press
Announcement
June 18, 2024
Iambic Therapeutics Closes $50 million Series B Extension to Broaden its Pipeline of AI-Discovered Clinical Oncology Programs
Read more
Press
Announcement
June 17, 2024
Iambic and NVIDIA: Using AI to chart a faster course for drug discovery
Read more
Press
Presentation
Announcement
May 23, 2024
Iambic Therapeutics Announces Poster Presentation for IAM1363, a Clinical Stage Type II HER2 Inhibitor, at the 2024 ASCO Annual Meeting
Read more
Press
Announcement
April 8, 2024
Podcast Discusses New Advances for Iambic's Clinical Oncology Study and its AI-Driven Drug Discovery Platform
Read more
Safety and Activity of IAM1363, a CNS-penetrant HER2 TKI in Participants with HER2 Altered Advanced Cancers
Publication
Presentation
October 23, 2026
Safety and Activity of IAM1363, a CNS-penetrant HER2 TKI in Participants with HER2 Altered Advanced Cancers
Read more
Publication
December 7, 2025
Scaling Multi-Modal and Multi-Task Transformers for Small Molecule Drug Discovery
Read more
Publication
December 3, 2025
San Diego NeuralPLexer3: Accurate Biomolecular Complex Structure Prediction with Flow Models
Read more
Publication
October 19, 2025
A Phase 1/1b Study of IAM1363, a selective and brain penetrant HER2 inhibitor in participants (pts) with advanced cancers harboring HER2 alterations (ESMO 2025)
Read more
Publication
September 9, 2025
IAM1363 is a Potent, Selective, and Irreversible HER2 and Pan-HER2 Mutant Small Molecule Inhibitor for the Treatment of HER2-Driven NSCLC
Read more
Publication
May 5, 2025
Enchant v2: Pushing the Boundaries of Predictive Drug Discovery
Read more
Publication
April 29, 2025
A Novel KIF18A Inhibitor for Targeting Chromosomal Instability in Cancer (AACR 2025 Poster)
Read more
Publication
December 16, 2024
NeuralPLexer3: Accurate Biomolecular Complex Structure Prediction with Flow Models
Read more
Publication
October 29, 2024
Enchant whitepaper: Breaking the data wall between lab and clinic
Read more
Safety and Activity of IAM1363, a CNS-penetrant HER2 TKI in Participants with HER2 Altered Advanced Cancers
Publication
Presentation
October 23, 2026
Safety and Activity of IAM1363, a CNS-penetrant HER2 TKI in Participants with HER2 Altered Advanced Cancers
Read more
Presentation
January 13, 2026
JPM Healthcare Conference 2026 Company Presentation
Read more
Presentation
October 30, 2025
Promise & Reality: Decoding AI’s Impact On Drug Development
Read more
Presentation
October 28, 2025
From Models to Medicines: Delivering on the Promise of AI-Driven Drug Discovery
Read more
Presentation
September 23, 2025
Enchant: A Multi-Modal Transformer Model to Break Down the Data Wall between Preclinical and Clinical Research and Development
Read more
Presentation
September 22, 2025
Leveraging AI/ML to Engineer Next-Generation HER2 Inhibitors with Enhanced Selectivity and Brain Penetrance
Read more
Presentation
September 10, 2025
Predictive Drug Discovery with Enchant v2
Read more
Presentation
August 18, 2025
Iambic will present new preclinical NSCLC data for IAM1363, a potent Type II HER2 inhibitor, at #WCLC25
Read more
Presentation
August 11, 2025
Fireside chat at the KeyBanc Capital Markets Technology Leadership Forum
Read more
For media requests
Contact our communications team at media@iambic.ai
Contact us
Better technology for better medicines
GET IN TOUCH
contact@iambic.ai
(619) 330-5499
COMPANY
AboutNews & MediaCareersContactInvestors
TECHNOLOGY
PlatformPipelinePartners
Privacy Policy
Terms of Use
Copyright © 2026 Iambic Therapeutics, Inc. All Rights Reserved.